Stay updated on Neratinib vs Lapatinib/Capecitabine in Advanced Breast Cancer Clinical Trial
Sign up to get notified when there's something new on the Neratinib vs Lapatinib/Capecitabine in Advanced Breast Cancer Clinical Trial page.

Latest updates to the Neratinib vs Lapatinib/Capecitabine in Advanced Breast Cancer Clinical Trial page
- Check12 days agoNo Change Detected
- Check19 days agoChange DetectedFooter updates include the addition of Revision: v3.3.3 and removal of the HHS Vulnerability Disclosure link as well as the Revision: v3.3.2 reference. These changes do not affect the study details or results. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check26 days agoNo Change Detected
- Check40 days agoChange DetectedThe page revision changed from v3.3.1 to v3.3.2; no study content or critical elements were altered. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check48 days agoChange DetectedThe page revision label was updated from v3.2.0 to v3.3.1.SummaryDifference0.1%

- Check55 days agoChange DetectedThe temporary operating-status notice about government funding was removed. Core study information and links remain unchanged.SummaryDifference0.4%

- Check69 days agoChange DetectedThe Outcome Measures section has been expanded to show current and original endpoints (PFS, OS, ORR, Clinical Benefit Rate, Duration of Response) with detailed definitions. This adds more detail on how outcomes are measured and the time frames for analysis.SummaryDifference0.1%

- Check98 days agoChange DetectedUpdate introduces a government-status notice and a new software version (v3.2.0), replacing the previous v3.1.0 mention.SummaryDifference4%

Stay in the know with updates to Neratinib vs Lapatinib/Capecitabine in Advanced Breast Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Neratinib vs Lapatinib/Capecitabine in Advanced Breast Cancer Clinical Trial page.